![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BioMarin’s Roctavian Gets EC Conditional Marketing Authorization for Severe Hemophilia A
BioMarin’s Roctavian Gets EC Conditional Marketing Authorization for Severe Hemophilia A
BioMarin Pharmaceutical’s gene therapy Roctavian (valoctocogene roxaparvovec) has received a conditional marketing authorization from the European Commission (EC) for treatment of patients with severe hemophilia A.
The one-time infusion treatment is the first approved gene therapy for hemophilia A, a condition that includes a mutation in the gene responsible for producing Factor VIII, a protein needed for blood clotting.
The treatment delivers a functional gene designed to enable the body to produce Factor VIII on its own.
The therapy is specifically authorized for adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5.
Upcoming Events
-
18Jul
-
21Oct